We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acute Phase Proteins as Early Markers in Sepsis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2008 by University of Zurich.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00641355
First Posted: March 24, 2008
Last Update Posted: March 24, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of Zurich
  Purpose

Monitoring of different serumproteins after severe trauma and during trauma-induced sepsis.

  • Trial with surgical intervention

Condition Intervention
Sepsis Procedure: No intervention

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Acute Phase Proteins as Early Markers in Sepsis

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Estimated Enrollment: 15
Study Start Date: April 2008
Estimated Study Completion Date: September 2012
Intervention Details:
    Procedure: No intervention
    No intervention
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with severe trauma
Criteria

Inclusion criteria:

  • Patients with severe trauma (ISS score > 16), both genders, patients on ICU

Exclusion criteria:

  • Moribund patients (pH <7,1, lactate >15mmol, Basedeficit > 15mEq/L, severe heart or liver injuries, GCS never over 5 after trauma)
  • Severe head injuries (AIS head >4)
  • Patient with severe infectious diseases, or diseases which severely affect the immune system (diabetes, Alkohol or nicotine abuse)
  • Non-german speaking patients
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00641355


Contacts
Contact: 01 Studienregister MasterAdmins +41 (0)44 255 11 11

Locations
Switzerland
Not yet recruiting
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Investigators
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

Responsible Party: PD Dr. Marius Keel, University Hospital of Zurich
ClinicalTrials.gov Identifier: NCT00641355     History of Changes
Other Study ID Numbers: StV 26-2007
First Submitted: March 17, 2008
First Posted: March 24, 2008
Last Update Posted: March 24, 2008
Last Verified: March 2008

Additional relevant MeSH terms:
Sepsis
Toxemia
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes